AstraZeneca PLC (AZN) Stock Price: $182.28+3.32 (+1.86%)
At close: Jun 11, 2026, 4:00 PM ET
The closing share price for AstraZeneca PLC (AZN) stock was $182.28 for Thursday, June 11, 2026, up 1.86% on the day.
Longer view (total return, dividends reinvested): past 12 months +25.2% · 3-year avg +9.1%/yr · 5-year avg +11.5%/yr
AZN Price Chart
AZN Key Metrics
See All MetricsAZN Earnings Preview
Next Earnings Date
Jul 27, 2026
45 days away
EPS Estimate
2.10
Revenue Est.
$15.47B
Last Quarter Results
EPS
$1.29
vs Estimate
$1.27
Revenue
$15.29B
vs Estimate
$14.93B
AZN Analyst Ratings
Consensus Rating
Based on 10 analysts
Average Price Target
$224.49
+23.2% upside
Low
$184.00
Current
$182.28
High
$245.00
AZN Analyst Estimates
Earnings Per Share (EPS) Estimates
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Q1 2026 | $2.44 | $2.52 | $2.72 | 3 |
| Q2 2026 | $1.41 | $2.50 | $2.90 | 3 |
| Q3 2026 | $2.65 | $2.68 | $2.70 | 2 |
| Q4 2026 | $2.47 | $2.52 | $2.58 | 1 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2027 | $6.55 | $11.66 | $12.77 | 7 |
| FY 2028 | $9.70 | $13.01 | $14.61 | 8 |
Revenue Estimates
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Q1 2026 | $14.67B | $14.93B | $15.22B | 9 |
| Q2 2026 | $15.19B | $15.47B | $15.70B | 7 |
| Q3 2026 | $16.00B | $16.19B | $16.32B | 7 |
| Q4 2026 | $16.51B | $16.75B | $17.08B | 4 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2027 | $64.64B | $67.90B | $69.82B | 18 |
| FY 2028 | $71.91B | $72.29B | $72.67B | 21 |
Source: FMP Analyst Consensus Estimates. Forward P/E calculated using average EPS estimate for the nearest fiscal year.
AZN Competitors' Key Metrics
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR |
|---|---|---|---|---|---|---|
| 1AZN | $282.69B | $182.28 | +1.86% | +25.21% | +11.47% | +16.00% |
AZN Charts
Valuation Charts
Performance Charts
CAGR Charts
Financial Statement Charts
- Revenue
- Gross Profit
- Operating Income
- Net Income
- EBITDA
- Free Cash Flow
- Operating Cash Flow
- Capital Expenditure
- Acquisitions
- Share Buybacks
- Stock-Based Compensation
- Total Assets
- Total Equity
- Cash & Equivalents
- Accounts Receivable
- Inventory
- PP&E
- Goodwill
- Accounts Payable
- Retained Earnings
- Total Debt
- Long-Term Debt
- Short-Term Debt
About AstraZeneca PLC
AstraZeneca PLC operates as a global biopharmaceutical leader, dedicated to the entire process of bringing prescription medicines to market, from their initial discovery and development through manufacturing and commercialization. The company's extensive portfolio of treatments, including prominent examples like Tagrisso, Farxiga, and Symbicort, addresses critical areas such as cardiovascular, renal, metabolic, and oncological conditions. Furthermore, it provides essential solutions for COVID-19 and various rare diseases, with products like Vaxzevria and Soliris. AstraZeneca engages with primary and specialty care physicians worldwide, facilitating distribution through a robust network of representatives and local offices across the United Kingdom, continental Europe, the Americas, Asia, Africa, and Australasia. The firm actively drives innovation through strategic collaborations, partnering with entities such as Neurimmune AG for the development and commercialization of NI006, BenevolentAI for systemic lupus erythematosus drug discovery, Lunit for AI-powered digital pathology risk assessment in NSCLC, and Absci Corporation for AI-driven oncology target identification. Founded in 1992, the company was initially known as Zeneca Group PLC, subsequently rebranding to AstraZeneca PLC in April 1999, and maintains its headquarters in Cambridge, United Kingdom.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- Pascal Claude Roland Soriot